Connect with us

Health

Early monoclonal antibody therapies beneficial for COVID-19, finds study – News-Medical.Net

A team of scientists recently conducted a large-scale study at Northwell Health, New York, USA, to evaluate the efficacy of neutralizing monoclonal antibody (MAB)…

Published

on

Article feature image

A team of scientists recently conducted a large-scale study at Northwell Health, New York, USA, to evaluate the efficacy of neutralizing monoclonal antibody (MAB) therapies in preventing disease progression among patients with mild to moderate coronavirus disease 2019 (COVID-19). The findings reveal that the timing of initiating MAB therapy is a crucial factor in determining its efficacy against COVID-19. The study is currently available on the medRxiv* preprint server.
Background
Since the emergence…

Click here to view the original article.

Continue Reading
Advertisement

You might also like ...

Article feature image
Mounting evidence suggests COVID vaccines do reduce transmission. How does this work? – Australian Times
Article feature image
Ibuprofen, other NSAIDs not tied to worse COVID illness, death – CIDRAP